Troglitazone Effects on Gene Expression in Human Skeletal Muscle of Type II Diabetes Involve Up-Regulation of Peroxisome Proliferator-Activated Receptor-γ1
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Troglitazone, besides improving insulin action in insulin-resistant subjects, is also a specific ligand for the nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ). To determine whether troglitazone might enhance insulin action by stimulation of PPARγ gene expression in muscle, total PPARγ messenger RNA (mRNA), and protein were determined in skeletal muscle cultures from nondiabetic control and type II diabetic subjects before and after treatment of cultures with troglitazone (4 days ± troglitazone, 11.5μ m). Troglitazone treatment increased PPARγ mRNA levels up to 3-fold in muscle cultures from type II diabetics (277 ± 63 to 630 ± 100 × 103 copies/μg total RNA, P = 0.003) and in nondiabetic control subjects (200 ± 42 to 490 ± 81, P = 0.003). PPARγ protein levels in both diabetic (4.7 ± 1.6 to 13.6± 3.0 AU/10 μg protein, P < 0.02) and nondiabetic cells (7.4 ± 1.0 to 12.7 ± 1.8, P < 0.05) were also up-regulated by troglitazone treatment. Increased PPARγ was associated with stimulation of human adipocyte lipid binding protein (ALBP) and muscle fatty acid binding protein (mFABP) mRNA, without change in the mRNA for glycerol-3-phosphate dehydrogenase, PPARδ, myogenin, uncoupling protein-2, or sarcomeric α-actin protein. In summary, we showed that troglitazone markedly induces PPARγ, ALBP, and mFABP mRNA abundance in muscle cultures from both nondiabetic and type II diabetic subjects. Increased expression of PPARγ protein and other genes involved in glucose and lipid metabolism in skeletal muscle may account, in part, for the insulin sensitizing effects of troglitazone in type II diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Henry, R. R., Abrams, L., Nikoulina, S., & Ciaraldi, T. P. (1995) · Diabetes · doi:10.2337/diab.44.8.936 · Cited by 233
Self-citation
Cited by
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
Beta Glucan: Health Benefits in Obesity and Metabolic Syndrome
El Khoury, D., Cuda, C., Luhovyy, B. L., & Anderson, G. H. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/851362 · Cited by 538
Effects of dietary fibers on disturbances clustered in the metabolic syndrome
Galisteo, M., Duarte, J., & Zarzuelo, A. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2007.02.009 · Cited by 477
The mode of action of thiazolidinediones
Hauner, H. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.249 · Cited by 411
PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer
Murphy, G. J., & Holder, J. C. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01559-5 · Cited by 386
The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes
Bouché, C., Serdy, S., Kahn, C. R., & Goldfine, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0026 · Cited by 346
Papathanasopoulos, A., & Camilleri, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.045 · Cited by 342
Way, J. M., Harrington, W. W., Brown, K. K., Gottschalk, W. K., Sundseth, S. S., Mansfield, T. A., Ramachandran, R. K., Willson, T. M., & Kliewer, S. A. (2001) · Endocrinology · doi:10.1210/endo.142.3.8037 · Cited by 338
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
Guan, Y., & Breyer, M. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00766.x · Cited by 295
Insulin Resistance with Aging: Effects of Diet and Exercise
Ryan, A. S. (2000) · Sports Medicine · doi:10.2165/00007256-200030050-00002 · Cited by 282
Thiazolidinediones in Type 2 Diabetes Mellitus: Current Clinical Evidence
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 277
Staiger, H., Haas, C., Machann, J., Werner, R., Weisser, M., Schick, F., Machicao, F., Stefan, N., Fritsche, A., & Häring, H.-U. (2009) · Diabetes · doi:10.2337/db07-1438 · Cited by 183
Insulin signaling and glucose transport in insulin resistant human skeletal muscle
Karlsson, H. K. R., & Zierath, J. R. (2007) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-007-0030-9 · Cited by 159
Rosiglitazone modifies the adipogenic potential of human muscle satellite cells
De Coppi, P., Milan, G., Scarda, A., Boldrin, L., Centobene, C., Piccoli, M., Pozzobon, M., Pilon, C., Pagano, C., Gamba, P., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0304-6 · Cited by 81
Al-Khalili, L., Forsgren, M., Kannisto, K., Zierath, J. R., Lönnqvist, F., & Krook, A. (2005) · Diabetologia · doi:10.1007/s00125-005-1741-3 · Cited by 78
“Direct effects of troglitazone have previously been reported on cell lipid metabolism [40], gene expression [41] and glucose uptake [39, 42] in human skeletal muscle.”
BackgroundTroglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans
Willi, S. M., Kennedy, A., Wallace, P., Ganaway, E., Rogers, N. L., & Garvey, W. T. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2895 · Cited by 77
Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes
Ciaraldi, T. P., Ryan, A. J., Mudaliar, S. R., & Henry, R. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158209 · Cited by 66
Self-citation
Metadata
- Authors
- Park, K. S., Ciaraldi, T. P., Lindgren, K., Abrams-Carter, L., Mudaliar, S., Nikoulina, S. E., Tufari, S. R., Veerkamp, J. H., Vidal-Puig, A., & Henry, R. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-08-01
- Volume
- 83
- Issue
- 8
- Pages
- 2830-2835
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2048080161
- Cited by
- 103
- References
- 3
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.